Orforglipron

Orforglipron is explicitly not a peptide — it is a synthetic, orally bioavailable small molecule engineered to activate the GLP-1 receptor without the manufacturing and delivery challenges that come with peptide-based GLP-1 drugs. It is included on PeptideWiki because it is directly comparable to, and frequently discussed alongside, injectable and oral peptide GLP-1 agonists already covered here (semaglutide, tirzepatide, retatrutide).

Developed by Eli Lilly, orforglipron received FDA approval in April 2026 (brand name Foundayo) for weight management in adults with obesity, or overweight with at least one weight-related comorbidity — approved in combination with reduced-calorie diet and increased physical activity. A separate submission for type 2 diabetes, based on the Phase 3 ACHIEVE program, was reported as pending at the time of this approval and should not be treated as approved.

Its central appeal is convenience: because it has no peptide backbone, it isn't digested by gut proteases the way peptide drugs are, so it needs neither an absorption-enhancer co-formulation (as oral semaglutide does) nor subcutaneous injection (as tirzepatide and retatrutide do). It can be taken with or without food and without water-timing restrictions.

Approval rested on the Phase 3 ATTAIN program; ATTAIN-1 (obesity/overweight without diabetes, n=3,127, 72 weeks) reported the highest-dose group losing an average of 12.4% body weight, with roughly 60% of that group losing at least 10%.

// NON-PEPTIDE GLP-1 RECEPTOR AGONISM

Orforglipron activates the GLP-1 receptor by binding within its transmembrane core, a different binding site than the one used by native GLP-1 and peptide agonists, which engage the receptor's extended extracellular domain. This distinct binding mode still stabilizes an active, Gs-coupled receptor conformation and drives cAMP signaling.

// WHY IT DOESN'T NEED INJECTION

Because it lacks a peptide backbone, orforglipron is not a substrate for the gut proteases that would otherwise digest a peptide drug — this is the specific structural reason it can be dosed as a simple oral tablet without the SNAC-style absorption enhancer that oral semaglutide requires, or the injection that tirzepatide and retatrutide require.

// EFFICACY POSITIONING VS. PEPTIDE GLP-1 DRUGS

Across cross-trial comparisons (not head-to-head data), orforglipron's weight-loss ceiling (~12% at 72 weeks in its pivotal trial) is described as broadly comparable to injectable semaglutide and below tirzepatide or retatrutide at their top doses — positioning it as "semaglutide-like efficacy in a pill" rather than a best-in-class outcome, with convenience as its primary differentiator.

ATTAIN-1 (Phase 3, obesity/overweight without diabetes, 72 weeks, n=3,127): highest-dose group lost an average of 12.4% body weight (~27.3 lbs); 59.6% of that group lost at least 10% body weight. Related trials ATTAIN-2 (obesity + type 2 diabetes population) and ATTAIN-MAINTAIN (weight-maintenance) also exist but supported secondary rather than the core approval claims.

Dosing: once-daily oral tablet, titrated from 0.8 mg up to a maximum of 17.2 mg in ~30-day steps (0.8 → 2.5 → 5.5 mg, then optional further titration to 9.0/14.5/17.2 mg); capped at 9 mg with strong CYP3A4 inhibitors.

Safety: typical GLP-1-class gastrointestinal effects (nausea, constipation, diarrhea, vomiting) most common; carries the class-wide boxed warning for thyroid C-cell tumor risk based on rodent carcinogenicity data, despite the label reportedly noting orforglipron itself was not active at rodent GLP-1 receptors in the specific carcinogenicity studies conducted — the warning is retained because human relevance of the class-wide rodent signal hasn't been ruled out. Contraindicated with a personal/family history of medullary thyroid carcinoma or MEN2.

No head-to-head randomized trial against tirzepatide or retatrutide was found; comparisons to those drugs in secondary sources are cross-trial only and shouldn't be treated as directly comparative data. The T2D indication (ACHIEVE program) had not been approved as of this entry's sourcing.